Sanofi
Suletud
44.46 0.66
Ülevaade
Aktsiahinna muutus
24h
Min
44.19
Max
44.94
Sissetulek | 2.4B 1.6B |
|---|---|
Müük | -961M 11B |
P/E Sektori keskmine | 19.257 50.102 |
Aktsiakasum | 1.1 |
Kasumimarginaal | 14.354 |
Töötajad | 74,846 |
EBITDA | -1.1B 2.7B |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +20.05% upside |
Turukapital | -9.1B 106B |
|---|---|
Eelmine avamishind | 43.8 |
Eelmine sulgemishind | 44.46 |
Sanofi Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Sanofi Prognoos
Hinnasiht
By TipRanks
20.05% tõus
12 kuu keskmine prognoos
Keskmine 53 USD 20.05%
Kõrge 57 USD
Madal 50 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
